Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints

JAMA Intern Med. 2017 Feb 1;177(2):276-277. doi: 10.1001/jamainternmed.2016.7761.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / pharmacology*
  • Biomarkers
  • Drug Approval / legislation & jurisprudence*
  • Drug Costs*
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / mortality
  • Neoplasms* / psychology
  • Quality of Life*
  • Survival Rate / trends
  • United States / epidemiology

Substances

  • Antineoplastic Agents
  • Biomarkers